Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on June 20, 2023, reporting events occurring on June 19, 2023. The filing addresses the appointment of a new Chief Financial Officer and Treasurer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the transition of Jennifer Cote from Interim Chief Financial Officer and Treasurer to the permanent role of Chief Financial Officer and Treasurer, effective June 19, 2023.
Management Commentary and Compensation Details
Ms. Cote entered into a one-year employment agreement with automatic annual extensions unless terminated by notice. Key compensation terms include:
- Base Salary: $300,000 annualized.
- Annual Bonus: Eligible for a target cash incentive of 50% of base salary beginning in fiscal year 2024.
- Equity: Eligible for annual long-term incentive equity awards beginning in fiscal year 2024; existing 2023 awards remain unaffected.
- Termination Benefits: In the event of termination without cause or for good reason, Ms. Cote is entitled to 12 months of base salary paid over one year, a pro-rata bonus, and one year of COBRA premiums. In a change-in-control scenario, the 12-month salary payment is made as a lump sum.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "good reason" and "without cause."
- Review the press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Confirm the status of Ms. Cote's existing equity awards under the 2021 Incentive Plan.
- Monitor future filings for the impact of this leadership change on the company's financial reporting and strategic direction.